JP2022532519A5 - - Google Patents
Info
- Publication number
- JP2022532519A5 JP2022532519A5 JP2021565055A JP2021565055A JP2022532519A5 JP 2022532519 A5 JP2022532519 A5 JP 2022532519A5 JP 2021565055 A JP2021565055 A JP 2021565055A JP 2021565055 A JP2021565055 A JP 2021565055A JP 2022532519 A5 JP2022532519 A5 JP 2022532519A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- composition according
- antibody
- lymphoma
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025166185A JP2026004466A (ja) | 2019-05-03 | 2025-10-02 | 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19172495.4 | 2019-05-03 | ||
| EP19172495 | 2019-05-03 | ||
| PCT/EP2020/062289 WO2020225196A1 (en) | 2019-05-03 | 2020-05-04 | Anti-cd19 therapy in patients having a limited number of nk cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025166185A Division JP2026004466A (ja) | 2019-05-03 | 2025-10-02 | 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022532519A JP2022532519A (ja) | 2022-07-15 |
| JP2022532519A5 true JP2022532519A5 (https=) | 2023-05-09 |
Family
ID=66647010
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021565055A Pending JP2022532519A (ja) | 2019-05-03 | 2020-05-04 | 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法 |
| JP2025166185A Pending JP2026004466A (ja) | 2019-05-03 | 2025-10-02 | 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025166185A Pending JP2026004466A (ja) | 2019-05-03 | 2025-10-02 | 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220242952A1 (https=) |
| EP (1) | EP3962943A1 (https=) |
| JP (2) | JP2022532519A (https=) |
| KR (1) | KR20220007087A (https=) |
| CN (1) | CN114072424A (https=) |
| AU (1) | AU2020267823A1 (https=) |
| CA (1) | CA3137664A1 (https=) |
| EA (1) | EA202193024A1 (https=) |
| IL (1) | IL287203A (https=) |
| MA (1) | MA55794A (https=) |
| MX (1) | MX2021013101A (https=) |
| MY (1) | MY209449A (https=) |
| PH (1) | PH12021552743A1 (https=) |
| SG (1) | SG11202111343TA (https=) |
| WO (1) | WO2020225196A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2767063C2 (ru) | 2015-08-21 | 2022-03-16 | МорфоСис АГ | Комбинации и их использование |
| US12358983B2 (en) | 2016-10-28 | 2025-07-15 | Incyte Corporation | Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| TW202525340A (zh) * | 2019-10-31 | 2025-07-01 | 美商英塞特公司 | 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US7320991B2 (en) | 2001-02-27 | 2008-01-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Analogs of thalidomide as potential angiogenesis inhibitors |
| WO2005016326A2 (en) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| CA2534639C (en) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anti-cd19 antibodies |
| CA2611814A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| ES2365046T3 (es) | 2005-12-30 | 2011-09-21 | Merck Patent Gmbh | Anticuerpos anti-cd19 con inmunogenicidad reducida. |
| PL2383297T3 (pl) * | 2006-08-14 | 2013-06-28 | Xencor Inc | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
| RU2495882C2 (ru) | 2006-09-08 | 2013-10-20 | Медиммун, Ллк. | Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания |
| EP2176298B1 (en) | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| CN102421800A (zh) | 2009-02-23 | 2012-04-18 | 格兰马克药品股份有限公司 | 结合cd19的人源化抗体及其用途 |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| FI3916392T3 (fi) * | 2016-05-30 | 2024-06-03 | Incyte Corp | Menetelmiä cd19-vasta-ainehoidon terapeuttisen hyödyn ennakoimiseksi potilailla |
-
2020
- 2020-05-04 AU AU2020267823A patent/AU2020267823A1/en active Pending
- 2020-05-04 MA MA055794A patent/MA55794A/fr unknown
- 2020-05-04 SG SG11202111343TA patent/SG11202111343TA/en unknown
- 2020-05-04 KR KR1020217039415A patent/KR20220007087A/ko active Pending
- 2020-05-04 CN CN202080044363.9A patent/CN114072424A/zh active Pending
- 2020-05-04 MX MX2021013101A patent/MX2021013101A/es unknown
- 2020-05-04 CA CA3137664A patent/CA3137664A1/en active Pending
- 2020-05-04 PH PH1/2021/552743A patent/PH12021552743A1/en unknown
- 2020-05-04 EA EA202193024A patent/EA202193024A1/ru unknown
- 2020-05-04 WO PCT/EP2020/062289 patent/WO2020225196A1/en not_active Ceased
- 2020-05-04 US US17/605,285 patent/US20220242952A1/en active Pending
- 2020-05-04 JP JP2021565055A patent/JP2022532519A/ja active Pending
- 2020-05-04 MY MYPI2021006219A patent/MY209449A/en unknown
- 2020-05-04 EP EP20722336.3A patent/EP3962943A1/en active Pending
-
2021
- 2021-10-12 IL IL287203A patent/IL287203A/en unknown
-
2025
- 2025-10-02 JP JP2025166185A patent/JP2026004466A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022532519A5 (https=) | ||
| AU2018233032B2 (en) | TEC family kinase inhibitor adjuvant therapy | |
| Cho et al. | Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside | |
| JP2023517243A5 (https=) | ||
| JP2023093495A5 (https=) | ||
| PT1616572E (pt) | Anticorpo quimérico anti-cd20, rituxan, para utilização no tratamento de leucemia linfocítica crónica | |
| JP2004512262A5 (https=) | ||
| JP2022523740A5 (https=) | ||
| CN107073122A (zh) | 恶性肿瘤的联合治疗 | |
| JP6764017B2 (ja) | がんの処置での使用のためのコビシスタット | |
| JP2019517485A5 (https=) | ||
| JP2019519770A5 (https=) | ||
| RU2019138222A (ru) | Применение ингибитора ezh2 в комбинации с ингибитором btk в получении лекарственного средства для лечения опухоли | |
| CN112074271A (zh) | 用于治疗淋巴瘤的方法 | |
| JP2018535996A5 (https=) | ||
| Chou et al. | Multidrug resistance gene expression in childhood medulloblastoma: correlation with clinical outcome and DNA ploidy in 29 patients | |
| WO2021124096A1 (en) | Once daily cancer treatment regimen with a prmt5 inhibitor | |
| Parisi et al. | Acute myelogenous leukemia: advances and limitations of treatment | |
| Vose | High-dose chemotherapy and hematopoietic stem cell transplantation for relapsed or refractory diffuse large-cell non-Hodgkin’s lymphoma | |
| Hamadani et al. | Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas | |
| Seiler et al. | Advances in the management of follicular lymphoma | |
| Garypidou et al. | Cardiac toxicity during rituximab administration | |
| RU2013106216A (ru) | Биомаркеры хронической лимфоцитарной лейкемии | |
| Chavez et al. | ABCL-412 Clinical Activity of CC-99282, a Novel, Oral, Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)–Results From CC-99282-NHL-001 (NCT03930953) a First-in-Human, Phase 1, Open-Label, Multicenter Study | |
| Pan et al. | DDDR-18. SINGLE-CELL FUNCTIONAL GENOMIC ANALYSIS OF PHARMACOLOGIC RESPONSES IN NF1 MUTANT GLIOBLASTOMA REVEALS DISTINCT MECHANISMS OF ACTION FOR MEK AND SHP2 INHIBITION |